166 related articles for article (PubMed ID: 38405908)
21. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.
Zhu Y; Ran T; Chen X; Niu J; Zhao S; Lu T; Tang W
Chem Pharm Bull (Tokyo); 2016; 64(8):1136-41. PubMed ID: 27477652
[TBL] [Abstract][Full Text] [Related]
22. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
23. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y; Huang J; Ivan C; Sun Y; Ma S; Mangala LS; Fellman BM; Urbauer DL; Jennings NB; Ram P; Coleman RL; Hu W; Sood AK
Gynecol Oncol; 2021 Oct; 163(1):181-190. PubMed ID: 34391578
[TBL] [Abstract][Full Text] [Related]
24. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus.
Hahn AS; Kaufmann JK; Wies E; Naschberger E; Panteleev-Ivlev J; Schmidt K; Holzer A; Schmidt M; Chen J; König S; Ensser A; Myoung J; Brockmeyer NH; Stürzl M; Fleckenstein B; Neipel F
Nat Med; 2012 Jun; 18(6):961-6. PubMed ID: 22635007
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
[TBL] [Abstract][Full Text] [Related]
26. A Novel Occulta-Type Spina Bifida Mediated by Murine Double Heterozygotes
Abdullah NL; Mohd-Zin SW; Ahmad-Annuar A; Abdul-Aziz NM
Front Cell Dev Biol; 2017; 5():105. PubMed ID: 29312933
[TBL] [Abstract][Full Text] [Related]
27. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
28. Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry.
Zhang H; Li Y; Wang HB; Zhang A; Chen ML; Fang ZX; Dong XD; Li SB; Du Y; Xiong D; He JY; Li MZ; Liu YM; Zhou AJ; Zhong Q; Zeng YX; Kieff E; Zhang Z; Gewurz BE; Zhao B; Zeng MS
Nat Microbiol; 2018 Feb; 3(2):1-8. PubMed ID: 29292383
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
Asquith CRM; Tizzard GJ; Bennett JM; Wells CI; Elkins JM; Willson TM; Poso A; Laitinen T
ChemMedChem; 2020 Jul; 15(13):1200-1215. PubMed ID: 32358915
[TBL] [Abstract][Full Text] [Related]
30. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
[TBL] [Abstract][Full Text] [Related]
31. BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals.
Pu S; Schor S; Karim M; Saul S; Robinson M; Kumar S; Prugar LI; Dorosky DE; Brannan J; Dye JM; Einav S
Antiviral Res; 2020 Dec; 184():104966. PubMed ID: 33137362
[TBL] [Abstract][Full Text] [Related]
32. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
33. Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
Asquith CRM; Treiber DK; Zuercher WJ
Bioorg Med Chem Lett; 2019 Jul; 29(14):1727-1731. PubMed ID: 31129055
[TBL] [Abstract][Full Text] [Related]
34. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.
Bekerman E; Neveu G; Shulla A; Brannan J; Pu SY; Wang S; Xiao F; Barouch-Bentov R; Bakken RR; Mateo R; Govero J; Nagamine CM; Diamond MS; De Jonghe S; Herdewijn P; Dye JM; Randall G; Einav S
J Clin Invest; 2017 Apr; 127(4):1338-1352. PubMed ID: 28240606
[TBL] [Abstract][Full Text] [Related]
35. Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2.
Tian JH; Liu WD; Zhang ZY; Tang LH; Li D; Tian ZJ; Lin SW; Li YJ
J Viral Hepat; 2019 Apr; 26(4):496-505. PubMed ID: 30521133
[TBL] [Abstract][Full Text] [Related]
36. Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.
Álvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2021 Feb; 211():113109. PubMed ID: 33360802
[TBL] [Abstract][Full Text] [Related]
37. Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis.
Gordon K; Kochkodan JJ; Blatt H; Lin SY; Kaplan N; Johnston A; Swindell WR; Hoover P; Schlosser BJ; Elder JT; Gudjonsson JE; Getsios S
J Invest Dermatol; 2013 Mar; 133(3):712-722. PubMed ID: 23190894
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr Virus gH/gL and Kaposi's Sarcoma-Associated Herpesvirus gH/gL Bind to Different Sites on EphA2 To Trigger Fusion.
Chen J; Schaller S; Jardetzky TS; Longnecker R
J Virol; 2020 Oct; 94(21):. PubMed ID: 32847853
[TBL] [Abstract][Full Text] [Related]
39. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
[TBL] [Abstract][Full Text] [Related]
40. Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily.
Rak M; Tesch R; Berger LM; Shevchenko E; Raab M; Tjaden A; Zhubi R; Balourdas DI; Joerger AC; Poso A; Krämer A; Elson L; Lučić A; Kronenberger T; Hanke T; Strebhardt K; Sanhaji M; Knapp S
Eur J Med Chem; 2023 Jun; 254():115347. PubMed ID: 37094449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
